OliX Pharmaceuticals and PCI Biotech announce a collaboration to combine OliX asiRNA and PCI Biotech fimaNAc technologies
Suwon, South Korea and Oslo, Norway, May, 5th 2021 – OliX Pharmaceuticals Inc. (KOSDAQ: 226950) a leading developer of RNAi therapeutics, and PCI Biotech (OSE: PCIB), a cancer focused biopharmaceutical company with a unique intracellular delivery technology, today announced an extensive research collaboration. OliX Pharmaceuticals and PCI Biotech will combine their know-how and technology platforms to explore synergies and further partnership on dermatology and other applications.
The partnership is governed by a research collaboration agreement, under which the collaborators will perform an extensive evaluation of technology compatibility and synergy based on OLX104C (Androgenic Alopecia) preclinical studies. The companies will evaluate results achieved from this research collaboration to explore the potential for further development and partnership.
Commenting on the announcement, Dong Ki Lee, CEO of OliX Pharmaceuticals said: “We are very excited to collaborate with PCI Biotech. Combining our proprietary asiRNA platform with PCI’s leading fimaNAc delivery technology will significantly accelerate our efforts to bring our dermatological RNAi programs to the clinic. We also expect to expand the area of application to our cancer immunotherapy pipeline and mRNA vaccines developed by our subsidiary, mCureX, in the near future.”
PCI Biotech’s CEO, Per Walday, added: “We are very pleased to initiate this exciting collaboration with OliX Pharmaceuticals. This collaboration builds on the strong potential of our intracellular delivery platform technology for nucleic acid based therapies, within a therapeutic field of good technological fit. Combining the leading technologies of OliX Pharmaceuticals and PCI Biotech may lead to new promising applications and we look forward to the collaboration.”
About OliX Pharmaceuticals
OliX Pharmaceuticals is a clinical stage pharmaceutical company developing therapeutics against a variety of disorders by down-regulating expression of disease-causing genes, based on its own proprietary RNAi technology. The Company’s core RNAi platform, asymmetric siRNA (asiRNA), is a unique gene silencing technology based on RNA interference (RNAi), which is considered as the most efficient gene silencing technology. Based on asiRNA technology, OliX has developed cell penetrating asiRNA (cp-asiRNA), a therapeutic RNAi platform to effectively target locally administrable diseases, such as hypertrophic scar, dry and wet age-related macular degeneration (AMD), subretinal fibrosis, idiopathic pulmonary fibrosis (IPF), and neuropathic pain. OliX has also developed another therapeutic RNAi platform, GalNAc-asiRNA, to target a variety of liver diseases. For more information, please visit: https://www.olixpharma.com
About PCI Biotech
PCI Biotech is a biopharmaceutical late stage clinical development company focusing on development and commercialization of novel therapies for the treatment of cancer through its innovative photochemical internalization (PCI) technology platform, for intracellular delivery. PCI induces triggered endosomal release that enables drugs to reach intracellular therapeutic targets. Currently, PCI Biotech is working on three programs: fimaChem (enhancement of chemotherapeutics for localized treatment of cancer), fimaVacc (T-cell induction technology for therapeutic vaccination), and fimaNAc (nucleic acid therapeutics delivery). For more information, please visit: www.pcibiotech.com
Contact Information:
OliX Pharmaceuticals
Media Contact
Kelly Kim / Communications
Phone: +82 10 4220 2801
E-Mail: kellykim@olixpharma.com
PCI Biotech Holding ASA
Per Walday, CEO Mobile: +47 917 93 429
E-Mail: pw@pcibiotech.com
Forward-looking statements
This announcement may contain forward-looking statements, which as such are not historical facts, but are based upon various assumptions, many of which are based, in turn, upon further assumptions. These assumptions are inherently subject to significant known and unknown risks, uncertainties and other important factors. Such risks, uncertainties, contingencies and other important factors could cause actual events to differ materially from the expectations expressed or implied in this announcement by such forward-looking statements. PCI Biotech disclaims any obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.
About GlobeNewswire by notified
GlobeNewswire by notifiedGlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.
Subscribe to releases from GlobeNewswire by notified
Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from GlobeNewswire by notified
CONDITIONS FOR RIKSBANK AUCTIONS GOVERNMENT BONDS26.4.2024 16:20:00 CEST | Press release
Bid procedure, 2024-05-03BondsSWEDISH GOVERNMENT: 1059. SE0007125927. 2026-11-12 SWEDISH GOVERNMENT: 1063, SE0015193313, 2045-11-24 Bid date2024-05-03Bid times09.00-10.00 (CET/CEST) on the Bid dateOffered volume (corresponding nominal amount)1059: 1000 million SEK +/-1000 million SEK 1063: 900 million SEK +/-900 million SEK Highest permitted bid volume (corresponding nominal amount)1059: 1000 million SEK per bid 1063: 900 million SEK per bid Lowest permitted bid volume (corresponding nominal amount)SEK 10 million per bidExpected allocation timeNot later than 10.15 (CET/CEST) on the Bid dateDelivery and payment date2024-05-07Settlement amountTo be paid to the Riksbank's account in Euroclear Sweden AB's securities settlement system SWIFT: VPCSSESSXXX Account: 1 4948 6383 CTM BIC: RIKSSESS ALERT acronym: RIKSBANK Stockholm, 2024-04-26 This is a translation of the special terms and conditions published on www.riksbank.se. In the case of any inconsistency between the English translation and
Press Release on the Filing of a Draft Offer Document Relating to the Simplified Tender Offer For the shares of Believe initiated by Upbeat BidCo SAS26.4.2024 15:20:00 CEST | Press release
PRICE OF THE OFFER: €15 per Believe share DURATION OF THE OFFER: 15 trading days The timetable of the tender offer (the “Offer”) will be set out by the Autorité des marchés financiers (the “AMF”) in accordance with the provisions of its General Regulation. This press release (the “Press Release”) was prepared by Upbeat BidCo and published pursuant to Article 231-16 of the General Regulation of the AMF. The offer and the draft offer document remain subject to review by the AMF. IMPORTANT NOTICE The Press Release must be read together with all other documents published in connection with the Offer. In particular, in accordance with Article 231-28 of the General Regulation of the AMF, a description of the legal, financial and accounting characteristics of Upbeat BidCo will be filed with the AMF and made available to the public no later than the day preceding the opening of the Offer. A press release will be issued to inform the public of the manner in which this information will be made a
The arbitral tribunal has confirmed GF’s redemption right over the minority shares in Uponor and trading in Uponor’s shares has been suspended26.4.2024 15:15:00 CEST | Press release
Uponor Corporation, Stock Exchange Release, April 26, 2024, 4.15 p.m. EET The arbitral tribunal has confirmed GF’s redemption right over the minority shares in Uponor and trading in Uponor’s shares has been suspended The arbitral tribunal appointed by the Redemption Committee of the Finland Chamber of Commerce in connection with the redemption proceedings concerning the minority shares in Uponor Corporation (“Uponor”) has in its interim award confirmed that Georg Fischer AG (“GF”) has the right to redeem the minority shares in Uponor and that GF has the right to obtain title to the minority shares by posting a security approved by the arbitral tribunal for the payment of the redemption price and the possible interest accruing thereon. Uponor announced on March 22, 2024, that Uponor has resolved to apply for the termination of public trading in its shares and for the delisting of its shares from the Official List of Nasdaq Helsinki Ltd (“Nasdaq Helsinki”) so that the delisting would occ
Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.)26.4.2024 15:00:00 CEST | Press release
ORION CORPORATION STOCK EXCHANGE RELEASE – MAJOR SHAREHOLDER ANNOUNCEMENTS 26 APRIL 2024 at 16.00 EEST Orion Corporation: Disclosure Under Chapter 9 Section 10 of the Securities Market Act (BlackRock, Inc.) Orion Corporation has received a disclosure under Chapter 9, Section 5 of the Securities Market Act, according to which the total number of Orion shares owned directly, indirectly and through financial instruments by BlackRock, Inc. and its funds decreased on 25 April 2024 below five (5) per cent of Orion Corporation’s total shares. Total positions of BlackRock, Inc. and its funds subject to notification: % of shares and voting rights (total of point A)% of shares and voting rights through financial instruments (total of point B)Total of both in % (points A + B)Total number of shares and voting rights of issuer Resulting situation on the date on which threshold was crossed or reached Below 5% shares Below 5% voting rights Below 5% shares Below 5% voting rights Below 5% shares Below
Decisions of the Organisational Meeting of Harvia Plc’s Board of Directors26.4.2024 15:00:00 CEST | Press release
STOCK EXCHANGE RELEASE 26 April 2024, at 4.00 p.m. EEST Decisions of the Organisational Meeting of Harvia Plc’s Board of Directors Heiner Olbrich was elected the Chair and Catharina Stackelberg-Hammarén was elected the Vice Chair of the Board of Directors at the Board of Directors’ organisational meeting that took place today after Harvia Plc’s Annual General Meeting. Board of Directors elected from among its members Hille Korhonen (Chair), Anders Holmén and Markus Lengauer as members of the Audit Committee. In addition, Harvia Plc’s Board of Directors decided to establish a Personnel and Remuneration Committee. The Committee’s task is to assist the Board of Directors in issues related to personnel and remuneration. The Board of Directors elected from among its members Heiner Olbrich (Chair), Olli Liitola and Catharina Stackelberg-Hammarén as members of the Personnel and Remuneration Committee. Independence of the members of the Board of Directors The Board of Directors assessed the in